

Special Issue

Diabetic Foot: New Devices and AI for Clinical Diagnosis and Therapies in Personalized Medicine

Message from the Guest Editors

The prevalence of diabetes has significantly increased worldwide. Likewise, diabetic foot (DF), one of the most feared conditions among chronic complications of diabetes, affects a growing number of patients. Diabetic foot can significantly impact the quality of life and survival of patients and has important direct and indirect consequences for patients and health systems.

Nowadays, the greater availability of new technologies and in particular systems and devices equipped with sensors and managed using AI solutions allows for the increasingly personalized treatment of patients. This Special Issue will present submissions detailing the most recent clinical findings of diabetic foot diseases, with a focus on innovative technologies and artificial intelligence (AI) applications for clinical diagnosis, case management and treatment.

Guest Editors

Dr. Piergiorgio Francia

Dr. Roberto Anichini

Dr. Leonardo Bocchi

Deadline for manuscript submissions

30 April 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/195536

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).